1. Academic Validation
  2. Genome-wide in vivo CRISPR screen identifies TGFβ3 as actionable biomarker of palbociclib resistance in triple negative breast cancer

Genome-wide in vivo CRISPR screen identifies TGFβ3 as actionable biomarker of palbociclib resistance in triple negative breast cancer

  • Mol Cancer. 2024 Jun 3;23(1):118. doi: 10.1186/s12943-024-02029-4.
Sophie Poulet 1 Meiou Dai 1 Ni Wang 1 Gang Yan 1 Julien Boudreault 1 Girija Daliah 1 Alan Guillevin 1 Huong Nguyen 1 Soaad Galal 1 Suhad Ali 1 Jean-Jacques Lebrun 2
Affiliations

Affiliations

  • 1 Department of Medicine, Cancer Research Program, McGill University Health Centre, Montreal, QC, Canada.
  • 2 Department of Medicine, Cancer Research Program, McGill University Health Centre, Montreal, QC, Canada. jj.lebrun@mcgill.ca.
Abstract

Triple negative breast Cancer (TNBC) remains exceptionally challenging to treat. While CDK4/6 inhibitors have revolutionized HR + breast Cancer therapy, there is limited understanding of their efficacy in TNBC and meaningful predictors of response and resistance to these drugs remain scarce. We conducted an in vivo genome-wide CRISPR screen using palbociclib as a selection pressure in TNBC. Hits were prioritized using microarray data from a large panel of breast Cancer cell lines to identify top palbociclib sensitizers. Our study defines TGFβ3 as an actionable determinant of palbociclib sensitivity that potentiates its anti-tumor effects. Mechanistically, we show that chronic palbociclib exposure depletes p21 levels, contributing to acquired resistance, and that TGFβ3 treatment can overcome this. This study defines TGFβ3 as an actionable biomarker that can be used to improve patient stratification for palbociclib treatment and exploits the synergistic interaction between CDK4/6 and TGFβ3 to propose a new combinatorial treatment for TNBC.

Figures
Products